Crossmark

Prolonged β2-agonist treatment enhances muscle-specific glucose uptake in individuals with overweight and obesity: a randomized placebo-controlled trial

Crossref DOI link: https://doi.org/10.1038/s41467-026-71897-9

Published Online: 2026-04-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Van Lier, Pip M. G.

van de Weijer, Tineke https://orcid.org/0000-0003-3485-7881
Vanweert, Froukje https://orcid.org/0000-0002-0005-8523
Brouwers, Kim

Nijssen, Kevin M. R.

Schaart, Gert https://orcid.org/0000-0003-4259-9528
Moonen-Kornips, Esther

van Beek, Sten M. M.

Springer, Sam https://orcid.org/0009-0007-8295-2521
Wierts, Roel

Joris, Peter J.

Schrauwen-Hinderling, Vera B. https://orcid.org/0000-0001-7795-584X
Phielix, Esther https://orcid.org/0000-0002-2672-0415
Bengtsson, Tore https://orcid.org/0000-0002-5396-030X
Schrauwen, Patrick

Hoeks, Joris https://orcid.org/0000-0002-0265-0870
Funding

Funding for this research was provided by:

Eureka EuroStars
License Information

Text and Data Mining valid from 2026-04-21

Accepted Manuscript valid from 2026-04-21
More Information

Article History

Received: 18 June 2025

Accepted: 2 April 2026

First Online: 21 April 2026

Competing interests

: Tore Bengtsson owns stock in Atrogi AB. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below